However, changes in ECM composition, such as the presence of laminin, can alter estrogen responsiveness and the effectiveness of antiestrogen therapies in estrogen receptor (ER)-positive breast cancer cells [24]. The gene discussed is LAMB2; the disease is breast carcinoma.